Premium
Melanoma cell lysis by human CTL clones: Differential involvement of T3, T8 and HLA antigens
Author(s) -
Fossati Giuseppe,
Anichini Andrea,
Parmiani Giorgio
Publication year - 1987
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910390606
Subject(s) - ctl* , monoclonal antibody , antigen , cytotoxicity , melanoma , lysis , human leukocyte antigen , immunology , biology , k562 cells , lymphocyte , immunotherapy , pan t antigens , microbiology and biotechnology , antibody , cancer research , immune system , in vitro , leukemia , genetics , cd8
Abstract Three lymphocyte clones, derived by micromanipulation from peripheral blood lymphocytes (PBL) of a melanoma patient and expressing a broad pattern of reactivity against different target cells, were analyzed for the involvement of T‐cell markers and HLA antigens in the lysis of target cells by blocking experiments with a panel of monoclonal antibodies (MAbs). The clones lysed autologous melanoma cells (Me 28) and 18 out of 22 allogeneic targets including neoplastic and normal cells of different histological origin. Anti‐T3 and anti‐T8 MAbs strongly inhibited the cytotoxicity of the lymphocyte clones against Me 28, 3 allogeneic melanomas and 3 carcinomas, but failed to affect the lysis of K562. Anti‐HLA class‐I MAb (w6/32) produced a significant enhancement of the lysis of Me 28 by the 3 clones without modifying cytotoxicity against one allogeneic melanoma or against K562 cells. Anti‐HLA class‐11 MAb (D1.12) did not affect the lysis of the same targets by the 3 clones. These results thus indicate that some anti‐melanoma CTL clones may interact with autologous tumor cells by the T3 and T8 structures in an HLA class‐1 unrestricted manner.